Ftorodeoksiglyukoza

[ ¹⁸ F]Ftordezoksiglyukoza (xalqaro patentlanmagan nomi (INN)) yoki ftrodezoksiglyukoza F18 ( (USAN va USP) ), shuningdek, odatda ftordezoksiglyukoza deb ataladi va qisqartirilgan $[^{18}F]FDG$ , $2[^{18}F]FDG$ yoki $FDG$ , radiofarmatsevtik preparat, pozitron emissiya tomografiyasi (PET) tibbiy tasvirlash usulida ishlatiladigan maxsus radioindikator. Kimyoviy jihatdan u $2-deoksi-2-[^{18}F]ftoro-D-glyukoza$ , glyukoza analogi bo'lib, glyukoza molekulasidagi C-2 pozitsiyasida normal gidroksil guruhi o'rniga pozitron chiqaradigan ftor-18 radionuklidiga ega.

$[^{18}F]FDG$ ning to'qimalar tomonidan o'zlashtirilishi glyukozaning to'qimalarda o'zlashtirilishining ko'rsatkichi bo'lib, bu o'z navbatida to'qimalar metabolizmining ayrim turlari bilan chambarchas bog'liqdir. Bemorga $[^{18}F]FDG$ yuborilgandan so'ng, PET skaneri tanadagi $[^{18}F]FDG$ [tarqalishining ikki o'lchovli yoki uch o'lchovli tasvirlarini yaratishi mumkin.

1976 yilda ishlab chiqilganidan beri $[^{18}F]FDG$ nevrologiya sohasidagi tadqiqotlarga katta ta'sir ko'rsatdi.^[1] 1980 yilda $[^{18}F]FDG$ ning o'smalarda to'planishi haqidagi keyingi kashfiyot PETning saraton tashxisida asosiy klinik vosita sifatida evolyutsiyasini yaratdi.^[2] $[^{18}F]FDG$ hoirgi kunda PET neyrotasvirini olish va saraton kasalligini davolash uchun ishlatiladigan standart radiofarmasevtik preparat hisoblanadi.^[3]

Tasvirlar turli xil tibbiy holatlarga tashxis qo'yish uchun yadro tibbiyot shifokori yoki rentgenolog tomonidan baholanishi mumkin.

Tarix[tahrir | manbasini tahrirlash]

1968 yilda chexoslavakiyadagi Karlova universitetining Organik kimyo kaferda doktori Yozef Pasak, Zdenek Tochik va Miloslav Cherniy FDG sintezini birinchi bo'lib tasvirladilar.^[4] Keyinchalik, 1970-yillarda Brukxaven milliy laboratoriyasida Tatsuo Ido va El Vulf birinchi bo'lib ftor-18 bilan belgilangan FDG sintezini tasvirlab berishdi.^[5] Birikmani birinchi marta 1976 yil avgust oyida Pensilvaniya universitetida Abass Alaviy tomonidan ikki oddiy inson ko'ngillilariga kiritilgan. Oddiy (PET emas) yadroviy skaner yordamida olingan miya tasvirlari ushbu organdagi $[^{18}F]FDG$ kontsentratsiyasini ko'rsatdi (quyida tarix ma'lumotiga qarang).

1990 yil avgust oyidan boshlab va 1991 yil davomida FDG uchun xom ashyo bo'lgan kislorod-18 ning yetishmasligi izotop zaxiralarini ratsionga kiritish zaruratini tug'dirdi. Isroilning kislorod-18 zavodi Fors ko'rfazi urushi tufayli yopildi va AQSh hukumati Los Alamos milliy laboratoriyasidagi uglerod, kislorod va azot izotoplari zavodini yopdi va Isotecni asosiy yetkazib beruvchi sifatida qoldirdi.^[6]

Yana qarang[tahrir | manbasini tahrirlash]

Ftorodopa

Foydalanilgan adabiyotlar ro'yxati[tahrir | manbasini tahrirlash]

↑ „Determination of regional cerebral function with FDG-PET imaging in neuropsychiatric disorders“. Seminars in Nuclear Medicine. 32-jild, № 1. January 2002. 13–34-bet. doi:10.1053/snuc.2002.29276. PMID 11839066.
↑ „A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection“. Journal of Nuclear Medicine. 21-jild, № 7. July 1980. 670–5-bet. PMID 7391842. {{cite magazine}}: Invalid |display-authors=6 (yordam)
↑ „Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development“. Clinical Cancer Research. 11-jild, № 8. April 2005. 2785–808-bet. doi:10.1158/1078-0432.CCR-04-2626. PMID 15837727. {{cite magazine}}: Invalid |display-authors=6 (yordam)
↑ „Synthesis of 2-Deoxy-2-fluoro-D-glucose“. Journal of the Chemical Society D: Chemical Communications. № 2. 1969. 77-bet. doi:10.1039/C29690000077.
↑ „Labeled 2-deoxy-D-glucose analogs: ¹⁸F-labeled 2-deoxy-2-fluoro-D-glucose, 2-deoxy-2-fluoro-D-mannose and ¹⁴C-2-deoxy-2-fluoro-D-glucose“. J Labeled Compounds Radiopharm. 24-jild, № 2. 1978. 174–183-bet. doi:10.1002/jlcr.2580140204.
↑ „Shortage of FDG raw material threatens expanded use of PET“. DiagnosticImaging (1992-yil 21-oktyabr).

Havolalar[tahrir | manbasini tahrirlash]

„Fludeoxyglucose F 18“. Drug Information Portal. U.S. National Library of Medicine.

Andoza:Radiopharmaceuticals

[1] „Determination of regional cerebral function with FDG-PET imaging in neuropsychiatric disorders“. Seminars in Nuclear Medicine. 32-jild, № 1. January 2002. 13–34-bet. doi:10.1053/snuc.2002.29276. PMID 11839066.

[2] „A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection“. Journal of Nuclear Medicine. 21-jild, № 7. July 1980. 670–5-bet. PMID 7391842. {{cite magazine}}: Invalid |display-authors=6 (yordam)

[3] „Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development“. Clinical Cancer Research. 11-jild, № 8. April 2005. 2785–808-bet. doi:10.1158/1078-0432.CCR-04-2626. PMID 15837727. {{cite magazine}}: Invalid |display-authors=6 (yordam)

[4] „Synthesis of 2-Deoxy-2-fluoro-D-glucose“. Journal of the Chemical Society D: Chemical Communications. № 2. 1969. 77-bet. doi:10.1039/C29690000077.

[Ido-5] „Labeled 2-deoxy-D-glucose analogs: ¹⁸F-labeled 2-deoxy-2-fluoro-D-glucose, 2-deoxy-2-fluoro-D-mannose and ¹⁴C-2-deoxy-2-fluoro-D-glucose“. J Labeled Compounds Radiopharm. 24-jild, № 2. 1978. 174–183-bet. doi:10.1002/jlcr.2580140204.

[6] „Shortage of FDG raw material threatens expanded use of PET“. DiagnosticImaging (1992-yil 21-oktyabr).

[1]

[2]

[3]

[4]

[5]

[6]